At Clinipace, a global, full-service contract research organization (CRO), our approach to clinical research is personal. We deliver a level of collaboration and flexibility not possible in a traditional CRO environment. Our personalized services and solutions, local regulatory expertise and therapeutic leadership are designed to face the most difficult industry challenges across all major therapeutic areas including oncology, gastroenterology, nephrology and urology. We strive to improve the way clinical research is performed and impact the future of health care using the most advanced technology and a CHALLENGE ACCEPTED approach. In April 2021, Clinipace & dMed merged creating a differentiated mid-size CRO with the largest Asia-Pacific presence. We are proud to have such a strong group of global investors focused on improving healthcare outcomes and giving sponsors a better CRO choice. dMed`s 2019 acquisition of Target Health commenced the process of building a Next Generation global CRO for biotech and pharmaceutical companies. Our investors have invested over $230M to build the next great global CRO. dMed`s acquisition of Target Health in 2019 began dMed`s evolution from a local to global CRO. Target Health LLC is owned by dMedClinical Co. Ltd., a privately held company that is majority owned, operated, managed, and controlled by a U.S. citizen and foreign entities located in the People`s Republic of China. Dr. Lingshi Tan, is the aforementioned U.S. citizen currently residing in Shanghai, China. Dr. Tan moved to Shanghai (from New York) to become Pfizer`s VP of Worldwide Development Operations, and Chairman and General Manager of Pfizer (China) Research & Development Co. Dr. Tan founded dMed in 2016 to satisfy the local demand for a high quality, responsive, flexible CRO.
Worldwide Clinical Trials is a global CRO providing full-service drug development services to the pharmaceutical and biotechnology industries from Early Phase and Bioanalytical Sciences through Phase II and III trials to peri-approval studies. Our team offers clients a wealth of expertise in neuroscience, cardiovascular, inflammation, rare disease, and other therapeutic areas. We successfully manage clinical trials with our own staff across nearly 60 countries in North America, Latin America, Europe, Asia Pacific and Middle East. Our full-service capabilities enable us to meet particular trial requirements without compromising on science, safety or service. Bioanalytical • Method Transfer and Validation • Pharmacokinetic Analysis and Reporting Clinical Research Services • Clinical Pharmacology • Bridging Studies • Dyna-Bridging Studies • Drug-Drug Interactions • Pharmacodynamic Modeling Clinical Development • Protocol Development • Feasibility • Project Management • Medical Monitoring • Clinical Monitoring • Site Management • Data Management • Rater Training • Biostatistics and Data Analysis • Medical Writing • Regulatory Affairs • Quality Assurance • Drug and Supply Depots • Drug Safety Peri-Approval • Product Safety and Pharmacovigilance • Late-Stage Research • Registries and Observational Studies • Health Outcomes, Epidemiology and Risk Management
The Y. For a better us.
TCP Reliable is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. TCP Reliable is based in Edison, NJ. You can find more information on TCP Reliable at www.tcpreliable.com
Histogenics is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal segment of the marketplace. Histogenics` regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions that can be utilized individually or in concert to treat musculoskeletal-related conditions. Histogenics` first investigational product candidate, NeoCart®, leverages its platform to provide an innovative treatment in the orthopedic space, specifically cartilage damage in the knee.